Phase 1 Trial: 177Lu-DTPA-SC16.56 in Neuroendocrine Prostate Cancer

/in , , /by

Neuroendocrine prostate cancer (NEPC) is a highly aggressive, treatment-resistant form of prostate cancer that emerges after androgen-deprivation therapies fail, leaving few effective options. Memorial Sloan Kettering Cancer Center is now running a Phase I trial testing a radiolabeled antibody called 177Lu-DTPA-SC16.56 in patients with progressive, chemotherapy-relapsed neuroendocrine prostate and lung cancers. DLL3 is the reason […]

Read more

UPDATE: Phase 3 Pivotal Trial for 177Lu-NYM032

/in , , /by

A PSMA-targeted radioligand built on a compound called NYM032 is heading into the pivotal phase 3 trial that will decide whether its early data hold up. The molecule can be labeled with gallium-68 for PET imaging or lutetium-177 for therapy, giving a matched diagnose-and-treat pair. In mouse tumor models, escalating the dose from 18.5 to […]

Read more

Beyond CRISPR? TIGRa: The Tiny Genetic Switch That Could Let the Body Heal Itself

/in , /by

Scientists at Stanford Medicine have built a new tool called TIGRa that can switch on helpful genes directly inside living cells. In a mouse study, it helped protect the eyes from a type of damage seen in glaucoma, and the discovery was published in the journal Cell Stem Cell. It could eventually lead to treatments […]

Read more

Soon to Be Phase 1: ADI‑212 Off The Shelf CAR T Therapy for mCRPC

/in , , /by

FDA has cleared the way for an early clinical trial of a new, off‑the‑shelf cell therapy designed to tackle metastatic castration‑resistant prostate cancer, a late and difficult stage of the disease. The investigational product, referred to in regulatory filings as ADI‑212, is a gene‑edited, “armored” gamma delta CAR T cell therapy that targets prostate‑specific membrane […]

Read more

Daily Adaptive Radiotherapy After Prostate Surgery: Early Results from the DART-PHASER Study

/in /by

A new clinical study is testing a smarter way to give radiation after prostate surgery. The approach, called daily adaptive radiotherapy, uses artificial intelligence to adjust the treatment plan every day based on how the patient’s anatomy looks at that moment. Early results from the first 42 patients in the DART-PHASER trial suggest the method […]

Read more

Forcing Resistant Prostate Cancer Back into Treatment Range: eIF4E Could Help

/in /by

Prostate cancer often becomes dangerous because the tumor cells can change their identity to escape treatment. At first, most prostate cancers are “luminal”: they depend on the androgen receptor (AR), a protein that acts like a growth switch turned on by male hormones. Drugs that block this receptor, such as enzalutamide, usually work well at […]

Read more

UPDATE: MRT-2359 Plus Apalutamide Combination Enters Phase 2 Trial for AR-Mutated Advanced Prostate Cancer

/in , , /by

A new phase 2 trial is evaluating MRT-2359 in combination with apalutamide for patients with androgen receptor (AR) mutation-positive metastatic castration-resistant prostate cancer, an advanced disease that may become resistant to standard hormone-directed treatments. The first patient has been dosed in the MODeFIRe-1 study, which plans to enroll up to 25 patients. Participants must have […]

Read more

Soon to be Phase 1 Trial: AK157D1 a New B7‑H3–Targeted ADC in Advanced Prostate Cancer

/in , , /by

The investigational B7‑H3–targeting antibody–drug conjugate AK157D1, recently cleared for a Phase I trial in advanced solid tumors, is especially compelling from a prostate cancer perspective because B7‑H3 (CD276) is one of the most uniformly expressed and biologically aggressive surface targets across the full disease continuum, from hormone‑sensitive to castration‑resistant and neuroendocrine phenotypes. Unlike PSMA, which […]

Read more